Related Experiment Videos
[Severe ischemic ventricular arrhythmia during dipyridamole scintigraphy]
Archives Des Maladies Du Coeur Et Des Vaisseaux
|June 1, 1991
Summary
Dipyridamole stress testing can rarely cause severe myocardial ischemia and ventricular tachycardia. This rare complication necessitates strict patient monitoring during the procedure, similar to exercise stress tests.
Area of Science:
- Cardiology
- Nuclear Cardiology
- Pharmacology
Background:
- Dipyridamole is a common pharmacologic stress agent used in myocardial scintigraphy.
- Myocardial ischemia during dipyridamole administration is typically mild and transient.
- Coronary artery disease patients are susceptible to ischemic events.
Observation:
- A case of severe myocardial ischemia with syncopal ventricular tachycardia occurred during dipyridamole injection.
- The patient had known coronary artery disease.
- The complication arose during Thallium myocardial scintigraphy.
Findings:
- Ventricular tachycardia is a rare but serious complication of dipyridamole stress testing.
- Myocardial ischemia, though uncommon, can be severe in susceptible individuals.
- Theophylline can be used to reverse dipyridamole-induced effects.
Implications:
- Strict patient surveillance is crucial during dipyridamole stress testing, akin to exercise stress testing.
- Awareness of potential severe complications is important for cardiologists and nuclear medicine physicians.
- This case highlights the need for preparedness in managing adverse cardiac events during pharmacologic stress tests.